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Network meta-analysis (NMA) can be used to compare multiple competing
treatments for the same disease. In practice, usually a range of outcomes is of
interest. As the number of outcomes increases, summarizing results from mul-
tiple NMAs becomes a nontrivial task, especially for larger networks. More-
over, NMAs provide results in terms of relative effect measures that can be
difficult to interpret and apply in every-day clinical practice, such as the odds
ratios. In this article, we aim to facilitate the clinical decision-making process
by proposing a new graphical tool, the Kilim plot, for presenting results from
NMA on multiple outcomes. Our plot compactly summarizes results on all
treatments and all outcomes; it provides information regarding the strength of
the statistical evidence of treatment effects, while it illustrates absolute, rather
than relative, effects of interventions. Moreover, it can be easily modified to
include considerations regarding clinically important effects. To showcase our
method, we use data from a network of studies in antidepressants. All analyses
are performed in R and we provide the source code needed to produce the
Kilim plot, as well as an interactive web application.
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1 | INTRODUCTION
Network meta-analysis (NMA) can be used to synthesize
direct and indirect evidence among many competing
interventions so as to guide clinical decisions.1 In practi-
cal applications of NMA there are usually many out-
comes of interest which play a role in the decision-
making process.2 However, effectively summarizing
results from NMAs on multiple outcomes can be chal-
lenging. The usual methods of presenting NMA results,
that is, showing relative effects vs a reference treatment
or via the so-called “league tables,” become difficult to
use as the number of treatments and outcomes increase.3
In such cases, implementing NMA results in clinical
practice can be very difficult.
Veroniki et al4 developed a heat plot aiming to facili-
tate the visualization of results obtained from multiple
outcomes NMA. To this aim, they used the results of
ranking statistics for interventions included in a NMA,
such as the surface under the cumulative ranking curve
(SUCRA).5 After fitting a NMA, a ranking statistic is cal-
culated for each outcome and then, using a color scheme,
results on all outcomes and treatments are compactly
visualized. The plot facilitates the identification of treat-
ments that perform well across all outcomes. Pillinger et
al6 presented a similar plot in a NMA for antipsychotics
on metabolic function in patients with schizophrenia. A
drawback of this approach is that ranking statistics (ie,
SUCRAs) do not have a straightforward clinical interpre-
tation, in contrast to estimated effect sizes and their
corresponding strength of statistical evidence; the latter
are arguably clinically more useful. Veroniki et al7 pres-
ented a rank-heat plot using the number needed to treat
(NNT); however, the use of NNT has been sometimes
criticized.8 Law et al9 used effect sizes and P-values to
visualize the network diagram; their approach, however,
may be impractical to use for the case of many outcomes.
Moreover, NMA results are usually presented in
terms of relative effects.10 This, however, can be problem-
atic, especially for binary outcomes. This is because clini-
cal significance hinges more on absolute outcomes, that
is, regarding the risk of an event occurring; or, in terms
of risk differences, rather than on odds ratios or risk
ratios. The latter are commonly used in fitting NMA, due
to their superior statistical properties, but may be hard to
use for practical decision-making purposes. In addition,
clinicians may also be interested in incorporating clini-
cally important values in their decisions. This is the case,
for example, when due to additional costs it is deemed
worthwhile to prescribe a new intervention when it
increases the probability of response by 10% or more as
compared to treatment as usual; or when the probability
of a side effect is increased by no more than 5% as
compared to the corresponding probability in placebo. In
such cases, published results from NMAs may not be very
informative, so as to guide decision among competing
drugs.
We hereby set out to develop a novel graphical tool,
the “Kilim plot” (named after a type of colorful rugs).
Our predefined goals when designing this tool were the
following: (a) to provide meta-analysts with a method for
summarizing and visualizing the evidence from multiple
What is already known?
• Network meta-analysis (NMA) can be used to
compare multiple competing treatments for
the same disease. A range of outcomes is usu-
ally of interest in a NMA.
• It can be difficult to efficiently summarize
results from NMAs on many outcomes, espe-
cially when the number of treatments in the
network and the number of outcomes is large.
• NMAs often provide results in terms of relative
effect measures that can be difficult to apply in
every-day clinical practice, such as the odds ratios.
What is new?
• We propose a new graphical tool, the “Kilim
plot,” aiming to facilitate the clinical decision-
making process.
• TheKilim plot can be used to visualize results from
NMA on multiple outcomes. It provides informa-
tion regarding the strength of statistical evidence of
treatment effects, and it illustrates absolute, rather
than relative, effects of interventions.
• The plot can include considerations regarding
clinically important effects.
Potential impact for RSM readers
outside the authors' field
• The Kilim plot can be a valuable aid in visualiz-
ing results from NMAs on multiple outcomes.
• It can be especially useful for larger networks,
for the case of many outcomes, and when
aiming to communicate NMA results with
patients and/or clinicians, so as to facilitate
every-day clinical practice.
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outcomes NMA; (b) to present results in terms of abso-
lute rather than relative effects; (c) to illustrate graphi-
cally the evidence with respect to clinically important
values.
To illustrate our tool we use a dataset that compares
antidepressants with respect to nine outcomes related to
treatment tolerability. We provide all R codes needed to
produce the graph in the Appendix and online (https://
github.com/MikeJSeo/phd/tree/master/kilim). Finally,
we illustrate the Kilim plot via an interactive web appli-
cation (https://cinema.ispm.unibe.ch/shinies/kilim/).




The dataset was based on a sample of 297 randomized
controlled trials about antidepressants for the acute treat-
ment of depression,11 using a predefined protocol.10 In
this working example, the studies compared seven anti-
depressants and placebo with respect to nine different
side effects (all binary outcomes). Three of the outcomes
were serious side effects, that is, suicidal ideation, aggres-
sion, and accidental overdose. The other six outcomes
corresponded to more frequent side effects, that is, nau-
sea, headache, dry mouth, insomnia, sexual dysfunction,
and diarrhea. According to the original protocol,10 the
ultimate aim is to compare 21 drugs across more than 35
outcomes. We hereby only use a subset of the entire
dataset, only for methodological purposes. To avoid a
potential use of our example in clinical practice, and also
due to confidentiality issues with respect to data, all drug
names have been anonymized in all results we show in
this article.
In Figure 1 we present the network graph for one out-
come only (ie, nausea). In Figure 2 we show the results
of the nine independent NMAs (one per outcome), for
each drug vs placebo.
3 | METHODS
In this section, we describe the procedure we follow in
order to draw the Kilim plot. For simplicity, we start by
focusing on the case of binary outcomes and then discuss
how the graph can be modified to accommodate continu-
ous outcomes as well. The overarching idea is to have a
table with a number of rows equal to the number of treat-
ments (rows = treatments), and columns equal to the
number of outcomes of interest (columns = outcomes).
In the first row, we place the reference treatment in the
network, for instance placebo, treatment as usual or stan-
dard care. Within each cell of the table (corresponding to
a treatment and an outcome), we provide information on
the point estimate of the absolute effects of the specific
treatment, for the specific outcome. As a visual aid, we
color the cells according to the strength of statistical evi-
dence of the relative effect of the treatment vs the refer-
ence, for the corresponding outcome. Note that by
“strength of statistical evidence” we hereby only refer to
the extent to which the estimated effects (taking into
account uncertainty) are either in favor or against each
treatment, as compared to a baseline treatment. In Sec-
tion 5, we discuss how the Kilim plot could be modified
to instead reflect quality of the evidence. Additional con-
siderations, such as comparisons of the estimated effects
to clinically important values can be accommodated in
the plot. Below, we describe this procedure in more
detail.
3.1 | Drawing the graph for a binary
outcome
The first step is to perform NMA for all outcomes. This
can be either a frequentist or a Bayesian NMA, using any
NMA model, for example, assuming fixed or random
effects, using odds ratios or risk ratios, accounting or not
for the correlations between the outcomes,12 and so on.
The output of the first step is estimates of relative treat-
ment effects for all outcomes of interest.
The second step is to obtain an estimate of the abso-
lute event rate for each outcome, for the reference inter-
vention. The obvious way to do this is to perform a meta-
analysis of all reference arms in the network. Alterna-
tively, we can use external information (eg, obtained
FIGURE 1 Network graph for nausea
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from an observational study) if the information is deemed
to be more relevant for clinical practice.
The third step is to combine the relative effects from
the first step and the reference treatment event rate from
the second step in order to estimate the event rates for all
treatments in the network. For example, let us assume
that we estimated in step one the odds ratio of treatment
X vs the reference to be OR Sð ÞX for outcome S. Also,
assume that for the reference treatment we estimated an
event rate equal to p Sð Þ0 in step two. Then, we can esti-
mate the event rate for treatment X, outcome S, denoted













this method so as to keep intact randomization (ie, rela-
tive effects are estimated from regular NMAs) and aiming
to obtain an estimate of absolute, rather than relative,
effects.
In the fourth step, we quantify the strength of statisti-
cal evidence, using the Z-score approach. Z-scores are
calculated using the estimated effect sizes and standard
errors obtained from the NMAs of step one, and possibly
taking also into account clinically important values (see
Section 3.3). More concretely, let us assume that in Step 1
we performed the NMAs in the odds ratios scale, and
we do not wish to further adjust for clinically
important values. In that case we simply calculate for
treatment X and outcome S, a Z-score equal to






. Note that for some of the
treatments in the network, we may not have any infor-
mation regarding outcome S. In that case we set the
corresponding Z-scores to zero.
In the fifth step, we draw the Kilim plot. The cell
corresponding to treatment X, outcome S is colored
according to Z Sð ÞX . Let us assume (ie, as in our example of
antidepressant dataset) that a negative Z-score is associ-
ated with a decrease in side effects when using an active
treatment. Then, we associate negative Z-scores with a
green color and positive Z-score with a red color. The
color becomes darker as Z Sð ÞX becomes larger (either nega-
tive or positive). White areas will correspond to cases
where we have limited information (Z Sð ÞX near zero). This
can be because the corresponding confidence intervals
are very wide or because a treatment is not included in
the network of S. Information regarding absolute event
rates is shown in the cells, using the results from step
three. The plot shows that a treatment is not included in
the network for a given outcome by denoting the missing
event rate with a dash.
Since Z-scores are related to P-values, and given that
the latter are more widely used to communicate
FIGURE 2 Network meta-analysis odds ratios for all outcomes, active vs placebo. In each figure, the drugs have been ordered
according to the corresponding point estimate of the odds ratios vs placebo
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uncertainty regarding an estimate, in the legend of the plot
we can provide information regarding the coloring scheme
in terms of P-values, instead of Z-scores. These are calcu-
lated from the Z-scores, using a two-sided test. Readers
should note that the plot will not be affected by the choice
between P-values or Z-scores for the legend. Readers
should also note that even though we use P-values, we do
not recommend dichotomizing results as “statistically sig-
nificant” or not. We discuss this further in Section 5.
3.2 | Drawing the graph for a continuous
outcome
For a continuous outcome, we can follow the same proce-
dure as above, if the analysis in step one is performed on
the natural scale, that is, using mean difference. Then, in
step two, we can estimate the mean endpoint result for
the reference treatment for each outcome, (or inform it
from an external source). In step three, we can estimate
the endpoint value for each treatment, using the mean
difference vs the reference (from step one) and the mean
estimate for the reference treatment (from step two). If
the standardized mean difference (SMD) is used (eg,
because studies report the outcomes using different
scales, and there is no way to convert between the scales),
then there is no straightforward way to obtain absolute
effects. One possible solution would be to express the




3.3 | Utilizing clinically important
values
We can modify the Kilim plot by incorporating clinically
important values (CIV) in step four above. Let us assume
that step one was conducted using odds ratios. Also
assume that we are interested in setting a clinically
important value of CIV Sð ÞRD =10% increase on the risk
compared to the reference, for outcome S. This might be
the case when S is a relatively minor side effect, and we
deem that an increase of up to 10% in the risk of S as
compared to placebo is acceptable. Then, using p Sð Þ0 and
CIV Sð ÞRD we can recalculate the corresponding CIV in the
odds ratio scale, CIV Sð ÞOR , and use it to obtain






=SE logOR Sð ÞX
 
. A negative
Z Sð ÞX will imply that X does not increase the risk of an
event by more than 10% as compared to the reference
and positive Z Sð ÞX will imply that X increases the risk by
more than 10%. If we instead specify a clinically impor-
tant value in the log-odds ratio scale (eg,
CIV Sð ÞOR = log 1:20ð Þ ), we can directly calculate Z Sð ÞX using
the formula above. Finally, note that the CIVs can be dif-
ferent per outcome.
4 | KILIM PLOT FOR THE
ANTIDEPRESSANTS EXAMPLE
In this section, we present the Kilim plot for the antide-
pressant data presented in Section 2.
4.1 | Implementation details
We performed all analyses in R. We ran the NMAs in
step one using the netmeta14 package. The analyses
were run on the odds ratio scale. We estimated the sum-
mary event rate in the placebo arms for each outcome in
step two using the metaprop function in meta15 pack-
age. The Kilim plot was drawn using the ggplot216
package. When coloring the Kilim plot, we truncated the
Z-score values. Values that were larger than 3 or smaller
than −3 were truncated to 3 and –3, respectively. This
was needed to prevent extremely large or small Z values
dominating one end of the color spectrum. To account
for different CIVs per outcome, we developed a web
application for our example using the shiny17 package.
The web application is available in https://cinema.ispm.
unibe.ch/shinies/kilim/. In addition to what we described
above, the web application also allows the users to manu-
ally set the placebo event rate. This might be useful when
different types of patients are deemed to have different
baseline risks (eg, when older patients may be more sus-
ceptible to a specific type of adverse events).
4.2 | Results
In Figure 3, we show the Kilim plot. The plot visualized
several aspects of the data and the analysis results. First,
the graph provides a quick overview of the treatments
being compared for each outcome. For example, for
aggression, three of the treatments (drug B, drug D, and
drug G) were not compared in the studies; the
corresponding cells in the aggression column are denoted
with a dash.
Next, the color of the cells facilitates the identification
of cases where the statistical evidence for the effect esti-
mate is strong either in favor of the drugs (green colors)
or in favor of placebo (red colors). For example, by
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looking at the column “dry mouth,” we see that there is
strong statistical evidence that all drugs perform worse
than placebo. Additionally, the numbers in the cells pro-
vide an estimate of the absolute effects. This might be
particularly important when trying to communicate
results to patients. For example, instead of informing a
patient that “drug A has an odds ratio of 12.6 versus pla-
cebo” (from Figure 2), using the Kilim plot a clinician
might instead provide the information that “Without tak-
ing the active drug, there is on average 9% probability of
having dry mouth. With drug A this probability is 54%.”
The corresponding color is dark red, implying that the
combination of magnitude and strength of statistical evi-
dence is convincing against drug A. Similarly, most drugs
appear to be detrimental for sexual dysfunction, with the
estimated event rate ranging from 3% to 11%, whereas in
placebo it was 4%. One of the drugs (drug D) has a light
green cell, meaning that the corresponding estimate (3%
rate) was not strong; thus, this estimate should not play a
big role either in favor or against the drug.
Some drugs perform consistently bad for all out-
comes, for example, drug B and drug C. On the other
hand, drug A and drug D, perform relatively better than
the rest of the treatments for most outcomes. In cases
when some of the outcomes are of particular importance
for a patient, then the decision on how to treat can be
guided accordingly, by focusing on the corresponding
columns.
In Figure 4, we show the Kilim plot from the same
dataset, but this time taking into account clinically
important values. More specifically, as an illustration we
assumed that for the non-serious adverse events an abso-
lute increase of 5% or less in the event rate may be clini-
cally not so important. For example, an increase of 5% or
less as compared to the risk in placebo might not be clini-
cally very meaningful when it comes to nausea. However,
for serious adverse events such as suicidal ideation, any
increase in the event rate, however small, was deemed to
be clinically important. Taking into account this set of
clinically important values (ie, nonserious outcomes: risk
difference 5%; serious outcomes: risk difference 0%), we
draw the Kilim plot of Figure 4. The estimated event rates
are the same as in Figure 3; this is because they are based
on the same analyses. The only difference regards the
colors of the non-serious outcomes. For instance, by
looking at the headache column, we now see that all
drugs are colored green. This is because, even though
almost all drugs perform worse than placebo, no drug is
estimated to lead to an increase of 5% or more in the
event rates. The maximum increase in risk is seen for
drug B, and it is equal to 2%; according to our rule, this
difference is deemed to be clinically unimportant. Using
this graph, a clinician or a patient might also decide to
consider drug G, in addition to drug A and drug D. The
full decision will of course need to be made by looking at
efficacy outcomes, not included in the data we used for
illustration.
Figure 4 can be redrawn using different thresholds for
the clinically important value of each different outcome.
For example, a patient might accept being prescribed a
FIGURE 3 Kilim plot for comparing antidepressant drugs for nine outcomes. The numbers in each cell correspond to the estimated
absolute event rates for each outcome and treatment. The colors correspond to the strength of statistical evidence regarding the relative
effects vs placebo. A cell with a deep green color indicates strong evidence that the corresponding drug performs better than placebo for the
corresponding outcome. Conversely, a deep red cell indicates strong evidence that the drug performs worse than placebo. Colors closer to
white indicate lack of evidence on whether the drug performs better or worse than placebo [Colour figure can be viewed at
wileyonlinelibrary.com]
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drug with an average 10% increase in the probability of
dry mouth or diarrhea, but might have zero tolerance (ie,
clinically important value of 0%) for insomnia and nau-
sea. In addition, this patient might belong to a high-risk
group regarding aggression, so that the corresponding
baseline probability of an event is deemed to be 10%
instead of 3%. Our web app can easily facilitate such
information, to draw a personalized Kilim plot.
5 | DISCUSSION
In this article, we have introduced a new graphical tool
for visualizing results from multiple outcomes NMA, the
Kilim plot. The aim of the Kilim plot is to provide a holis-
tic view of the available evidence expressed in terms of
absolute treatment effects and their corresponding
strength of statistical evidence.
First, the plot provides information regarding the esti-
mated absolute effects for the baseline treatment in the
network, for all outcomes. These are estimated from ana-
lyses of the baseline arms in all studies. Second, the plot
provides information on the absolute effects for all non-
baseline treatments. These are estimated using the results
from the NMA (ie, relative effects) and the estimated
effects for the baseline treatment, for each outcome. Fur-
thermore, using a coloring scheme, the Kilim plot pro-
vides information on which treatments there is strong
statistical evidence that they have a beneficial effect (deep
green colors) and on which treatments there is strong evi-
dence that they have a detrimental effect (deep red
colors), for each outcome. Additionally, the Kilim plot
incorporates features which are potentially useful to cli-
nicians and patients, that is, it can include considerations
regarding clinically important values and it allows users
to input baseline event rates.
The Kilim plot does not provide information on rela-
tive effects, for example, odds ratios or risk differences.
Also, it does not show confidence intervals; instead it
uses a coloring scheme to communicate uncertainty.
Thus, the Kilim plot can be used to augment (but not
replace) the usual methods of presenting results from
NMA, such as league tables and plots of relative effects vs
a reference treatment (as in Figure 2). Our plot shares
some similarities with the rank-heat plot,4 that is, both
are methods for visualizing results from multiple out-
comes NMA. However, the Kilim plot aims at providing
information on absolute effects, while the rank-heat plot
is focused on ranking metrics (eg, SUCRAs). Moreover,
the Kilim plot can visualize the evidence with respect to
clinically important values.
The reason why we included information on absolute
rather than relative effect in the graph is because the lat-
ter are usually hard to interpret and utilize in every-day
clinical practice, especially for binary outcomes. For
example, a risk ratio of 2.5 can have very different impli-
cations, depending on whether the baseline event rate is
1% or 10%; moreover, most people would have a hard
FIGURE 4 Kilim plot for the antidepressants example, with color adjustment for clinically important values. For nonserious outcomes
(ie, all outcomes except suicidal ideation, aggression, accidental overdose) the clinically important value is set to a risk increase of 5%. Dark
green cells for these outcomes indicate strong statistical evidence that the corresponding drug leads to an increase of event rate less than 5%
as compared to placebo, for the corresponding outcome. Dark red cells indicate strong evidence that the drug increases the event rate by 5%
or more. White cells indicate lack of evidence on whether the effects of drugs reach the clinically important values, for example, when the
corresponding confidence intervals spans from values smaller than 5% to values larger than 5% [Colour figure can be viewed at
wileyonlinelibrary.com]
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time understanding the meaning of an odds ratio of 1.7,
let alone use multiple odds ratios regarding different out-
comes to make a clinical decision among competing
treatments. Readers should note at this point that the
Kilim plot bears similarities with the summary of find-
ings table in Cochrane reviews.13 Such a table summa-
rizes results of a systematic review by showing measures
of absolute effects without the intervention, measures of
absolute effects with the intervention, and also relative
treatment effects.
Our method keeps intact randomization (ie, relative
effects are estimated from regular NMAs) and aims to
obtain an estimate of absolute, rather than relative,
effects. Alternatively, a so-called “arm-based” NMA
model18 could have been used in step one of Section 3.1,
to directly estimate event rates. Arm-based models, how-
ever, have received some criticism19; thus, we here pres-
ented how to estimate absolute event rates using the
usual “contrast-based” models.
Our readers should also note that although we use P-
values to communicate uncertainty, we do not use or pro-
mote the concept of “statistical significance,” that is, we
have avoided dichotomizing the evidence as significant
or not according to an arbitrary threshold, such as P-
value = .05 or any other value. Statistical significance has
been a target for much criticism in science in general,20
and especially for NMA.21 We hereby also recommend
meta-analysts to avoid using it to characterize NMA
results.
One limitation of our approach is that in order to esti-
mate absolute event rates, we assume that relative effects
are independent of the absolute effects for the reference
treatment. For example, we described how we first esti-
mate odds ratios using a regular NMA, and then how we
apply these odds ratios to a baseline risk (ie, risk in pla-
cebo), to estimate absolute event rates for all treatments.
Information on the baseline risk can be obtained using
an external source of information. However, odds ratios
may be correlated to baseline risk, for example, when a
drug works better in more severely ill patients. In such
cases, our approach will lead to biased estimates; in these
scenarios it might be advisable to avoid using external
sources of information for estimating the baseline risk.
To further facilitate decision-making, the Kilim plot
can be modified to account for clinically important values.
For example, we might have strong evidence that a drug
increases the probability of headache by 1% (confidence
interval 0.5%-2.5%) as compared to placebo. However, this
small increase might be clinically irrelevant, despite its
strong statistical evidence. In this article, we have discussed
how such considerations can be incorporated in such a
plot, by changing the coloring scheme. Other possible
extensions for the Kilim plot would be to show confidence
intervals for the event rates; to use different font sizes for
the event rates, depending on the precision of the relative
effects; to group treatments by class; to indicate in the plot
whether the estimates for each treatment vs the baseline
were derived from direct, indirect, or mixed evidence; to
group outcomes by their type, for example, efficacy/accept-
ability/safety; to use different coloring schemes for different
classes of outcomes; to color the cells after using the CIN-
EMA approach22 to assess the quality of the evidence
(online tool available in https://cinema.ispm.unibe.ch/).
We hereby did not pursue such extensions, aiming to keep
the plot as simple as possible.
To illustrate the Kilim plot we utilized a dataset from
depression, where seven drugs and placebo were com-
pared for nine different outcomes. Although our example
only used dichotomous outcomes, an extension of the
plot for continuous outcomes would be straightforward.
All codes needed to produce the Kilim plot are provided
in the Appendix and online. In addition, we developed
an example web application using R shiny, to illustrate
how the graph can be adjusted for different choices of
clinically important values and/or different baseline
risks. The code for the web app can also be found in the
Appendix and online.
In summary, we believe that the Kilim plot can be a
valuable aid in summarizing and communicating results
from NMAs on multiple outcomes. It can be especially
useful for larger networks, for the case of many out-
comes, and when aiming to communicate NMA results
with patients and/or clinicians, so as to facilitate every-
day clinical practice.
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